Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 397-400

  Ho, Chao Hung ^a   Yuan, Chiou Chung ^a   Liu, Shian Min ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Diagnostic value; Fibrinolysis markers; Ovarian cancers; Prognostic value

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKER; UROKINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TISSUE DISTRIBUTION;

EID: 0032795856     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5610     Document Type: Article

References (16)

1. Kruithof E KO. Biological evaluation of the fibrinolytic system. Fibrinolysis. 7:1993;7-9.
2. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Fibrinolysis. 7:1993;17-18.
3. Binder B R. Fibrinolytic markers of clinical evolution in tumour patients. Fibrinolysis. 7:1993;21-23.
4. Chambers S K, Ivins C M, Carcangiu M L. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1. Am J Cancer. 74:1997;571.
5. Ruppert C, Ehrenforth S, Scharrer I, Halberstadt E. Protease levels in breast, ovary and other gynecological tumor tissues: prognostic importance in breast cancer. Cancer Detect Prev. 21:1997;452-459.
6. Chambers S K, Ivins C M, Carcangiu M L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer. 79:1998;449-454.
7. Gleeson N C, Hill B J, Moscinski L C, Mark J E, Roberts W S, Hoffman M S, Fiorica J V, Cavanagh D. Urokinase plasminogen activator in ovarian cancer. Eur J Gynecol Oncol. 17:1996;110-113.
8. Chambers S K, Gertz R E Jr, Ivins C M, Kacinski B M. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer. 75:1995;1627-1633.
9. Heiss M M, Babic R, Allgayer H, Gruetzner K U, Jauch K W, Loehrs U, Schildberg F W. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol. 13:1995;2084-2093.
10. Piver, M, S, Fanning, J, Craig, K, A, Ovarian cancer, in, Knapp, R, C, Berkowitz, R, S, (eds), Gynecologic Oncology, New York, McGraw-Hill, 1993, pp 192-221.
11. Smith P K, Krohn R I, Hermanson G T, Mallia A K, Gartner F H, Provenzano M D, Fulimoto E K, Goeke N M, Olson B J, Klenk D C. Measurement of protein using bicinchoninic acid. Anal Biochem. 150:1985;76-85.
12. Ho C H, Chao Y, Lee S D, Chau W K, Wu C W, Liu S M. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer. Thromb Res. 91:1998;23-27.
13. Juhan-Vague, I, Aillaud, M, F, De Cock, F, Philip-Joet, C, Arnaud, C, Serradimigni, A, Collen, D, The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant protein, in, Davidson, J, F, Donati, M, B, Coccheri, S, (eds), Progress in Fibrinolysis, Edinburgh, Churchill-Livingstone, 1985, pp, 146, - 149.
14. Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 51:1991;3690-3695.
15. Reilly D, Christensen L, Duch M, Nolan N, Duffy M J, Andreasen P A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer. 50:1992;208-214.
16. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer. 50:1992;345-348.